At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 11-09 16:08:05
4.705
+0.155
+3.41%
High5.065Low4.560Vol2.18M
Open4.560D1 Closing4.550Amplitude11.10%
Mkt Cap4.95BTradable Cap4.95BTotal Shares1.05B
T/O10.51MT/O Rate0.21%Tradable Shares1.05B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma-B Repurchases 200,000 Shares for HK$960,600 on November 5
Stock News  ·  11-05
Ascletis Pharma-B Repurchases 200,000 Shares for HK$960,600 on November 5
Ascletis Pharma Files HKEX Return Announcing Share Buyback for Cancellation
Reuters  ·  11-05
Ascletis Pharma Files HKEX Return Announcing Share Buyback for Cancellation
Ascletis Issues 1.80 Million Employee Stock Options, Setting HK$4.923 Exercise Price
Bulletin Express  ·  11-04
Ascletis Issues 1.80 Million Employee Stock Options, Setting HK$4.923 Exercise Price
Ascletis Pharma-B Grants 1.8 Million Share Options
Stock News  ·  11-04
Ascletis Pharma-B Grants 1.8 Million Share Options
Ascletis-B Keeps October Share Base Steady; 5.50 Million Repurchased Shares Await Cancellation
Bulletin Express  ·  11-04
Ascletis-B Keeps October Share Base Steady; 5.50 Million Repurchased Shares Await Cancellation
Hong Kong Stock Movers: Innovative Drug Concept Stocks Extend Losses, GENSCRIPT B-1K (01548) Plunges Over 15%, KEYMED BIO-B (02162) Drops Nearly 5%
Stock News  ·  11-03
Hong Kong Stock Movers: Innovative Drug Concept Stocks Extend Losses, GENSCRIPT B-1K (01548) Plunges Over 15%, KEYMED BIO-B (02162) Drops Nearly 5%
Ascletis Pharma Files HKEX Next Day Disclosure Return on Share Buyback for Cancellation
Reuters  ·  10-30
Ascletis Pharma Files HKEX Next Day Disclosure Return on Share Buyback for Cancellation
Ascletis Pharma-B Repurchases 100,000 Shares for Approximately HK$525,400 on October 29
Stock News  ·  10-29
Ascletis Pharma-B Repurchases 100,000 Shares for Approximately HK$525,400 on October 29
Hong Kong Stock Announcement Highlights: Ping An's First Three Quarters Net Profit Attributable to Shareholders Reaches 96.645 Billion Yuan, Continues to Deepen "Comprehensive Finance + Healthcare and Elderly Care" Dual-Wheel Parallel, Technology-Driven Strategy
Stock News  ·  10-29
Hong Kong Stock Announcement Highlights: Ping An's First Three Quarters Net Profit Attributable to Shareholders Reaches 96.645 Billion Yuan, Continues to Deepen "Comprehensive Finance + Healthcare and Elderly Care" Dual-Wheel Parallel, Technology-Driven Strategy
Ascletis Pharma-B (01672) Reports Oral GLP-1 Candidate ASC30 Achieves 1.7% Placebo-Adjusted HbA1c Reduction at Week 12 in U.S. Phase II Diabetes Trial
Stock News  ·  10-29
Ascletis Pharma-B (01672) Reports Oral GLP-1 Candidate ASC30 Achieves 1.7% Placebo-Adjusted HbA1c Reduction at Week 12 in U.S. Phase II Diabetes Trial
Ascletis' ASC30 Cuts HbA1c by up to 1.7% Versus Placebo in Phase II Diabetes Trial
Reuters  ·  10-29
Ascletis' ASC30 Cuts HbA1c by up to 1.7% Versus Placebo in Phase II Diabetes Trial
Ascletis Highlights Robust U.S. Phase II Data for Oral GLP-1 Candidate ASC30; Demonstrates 1.7% Placebo-Adjusted HbA1c Decline at 12 Weeks
Bulletin Express  ·  10-29
Ascletis Highlights Robust U.S. Phase II Data for Oral GLP-1 Candidate ASC30; Demonstrates 1.7% Placebo-Adjusted HbA1c Decline at 12 Weeks
Ascletis' Oral Small Molecule Glp-1, Asc30, Demonstrated Placebo-Adjusted Hba1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase Ii Study in Participants with Diabetes
THOMSON REUTERS  ·  10-29
Ascletis' Oral Small Molecule Glp-1, Asc30, Demonstrated Placebo-Adjusted Hba1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase Ii Study in Participants with Diabetes
Ascletis Pharma Reports 5.10 Million-Share Buy-Back; HKD 37.87 Million Spent Since June
Bulletin Express  ·  10-27
Ascletis Pharma Reports 5.10 Million-Share Buy-Back; HKD 37.87 Million Spent Since June
Ascletis Pharma Repurchases 100,000 Shares for About HK$558,800 on October 26
Stock News  ·  10-26
Ascletis Pharma Repurchases 100,000 Shares for About HK$558,800 on October 26
Ascletis Pharma Inc. Says FDA IND Submission of ASC39
Reuters  ·  10-26
Ascletis Pharma Inc. Says FDA IND Submission of ASC39
Ascletis Pharma-B (01672) Submits IND Application to U.S. FDA for ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for Obesity Treatment
Stock News  ·  10-26
Ascletis Pharma-B (01672) Submits IND Application to U.S. FDA for ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for Obesity Treatment
Ascletis Files FDA IND for ASC39, a Highly Selective Oral Amylin Receptor Agonist Aimed at Obesity Treatment
Bulletin Express  ·  10-26
Ascletis Files FDA IND for ASC39, a Highly Selective Oral Amylin Receptor Agonist Aimed at Obesity Treatment
Ascletis Pharma Files FDA Application to Test Obesity Drug ASC39
Reuters  ·  10-26
Ascletis Pharma Files FDA Application to Test Obesity Drug ASC39
Ascletis Pharma Inc. - FDA Ind Submission of Asc39, an Oral- Small Molecule Selective Amylin Receptor Agonist For- Treatment of Obesity
THOMSON REUTERS  ·  10-26
Ascletis Pharma Inc. - FDA Ind Submission of Asc39, an Oral- Small Molecule Selective Amylin Receptor Agonist For- Treatment of Obesity

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--